mlkrborn
12 년 전
Globus Medical sees Q4 revs of $100.5 mln vs $97.9 mln Capital IQ Consensus Est (GMED) 12.32 : Co announced preliminary unaudited sales results for the year ending December 31, 2012, in advance of its national sales meeting being held later this week. The co anticipates Q4 sales of $100.5 million, a 14.3% increase over Q4 2011, and full year 2012 sales of $386.0 million, a 16.4% increase over 2011.
"Our business remains robust, and Q4 performance is a testament to the consistent execution of our strategy. We believe we will continue to grow our business at rates significantly above the industry by innovating in rapid response to the needs of our customers and patients, growing our US sales force, and expanding our footprint internationally."
midastouch017
12 년 전
Reborn???
Globus Medical Announces Pricing of Initial Public Offering
Date : 08/03/2012 @ 8:46AM
Source : Business Wire
Stock : Globus Med Com USD0.001 A (GMED)
Quote : 0.001 0.0 (0.00%) @ 2:05AM
Globus Medical, Inc. (NYSE:GMED), a leading spinal implant manufacturer, today announced the pricing of its initial public offering of 8,333,333 shares of Class A common stock at a price of $12 per share, consisting of 2,083,333 shares offered by Globus Medical and 6,250,000 shares offered by selling stockholders. In addition, Globus Medical has granted the underwriters a 30-day option to purchase up to an additional 1,250,000 shares of common stock to cover any over-allotments. Closing of the offering is expected to occur on August 8, 2012, subject to customary closing conditions. The shares are expected to begin trading on the New York Stock Exchange today under the symbol GMED.
midastouch017
15 년 전
SEC Suspends Trading in GenoMed Shares; Company's Response
Contact:
David W. Moskowitz MD
CEO, GenoMed
Tel. 314-983-9933
dwmoskowitz@genomed.com
March 4, 2010—GenoMed® (OTC Pink Sheets GMED.PK), the Public Health Company™, announced today that the Securities and Exchange Commission suspended trading in its shares today because the company is delinquent in its SEC filings.
Dr. David Moskowitz, GenoMed's CEO, said, "We are committed to trading on the Pink Sheets again as soon as possible. The problem is money. In the past, auditors and attorneys have charged us on the order of $50,000 a year to file our SEC reports, even though the reports have been quite simple. In September, 2005, we ran out of money to pay auditors and attorneys. I stopped taking a paycheck from GenoMed in May, 2005. For the past few years, I've been supporting the company out of my retirement money. Although I've been working for free since 2005, I haven't found any attorneys or auditors willing to do so."
Dr. Moskowitz continued, "We're trying to bring money into the company just as single-mindedly as before. We're pursuing joint ventures to develop so-called 'kind' chemotherapy: non-toxic pills that slow cancer down. We're also marketing directly to patients with diabetes, high blood pressure, or emphysema."
Dr. Moskowitz ended by saying, "I remain committed to all the company's investors. I am one myself. Becoming compliant with the SEC again should have the effect of an IPO, with a resultant increase in our share price. Most importantly, I believe in our mission to transform healthcare: to save lives while lowering costs. I continue to believe that it's only a matter of time before word leaks out, especially to Baby Boomers, that we can prevent 90% of kidney failure and save Medicare 10% of its budget. It's not our fault that Medicare doesn't want to."
About GenoMed (www.genomed.com)
GenoMed was founded in 2001 by Dr. David Moskowitz, a kidney specialist. The company recently began a "Dialysis-Free in 5" campaign: it will gladly work with any community in the world that wants to eliminate 90% of dialysis within 5 years. GenoMed hopes to make the St. Louis area dialysis-free by 2015.
midastouch017
15 년 전
Civil Rights Activist Lawrence Guyot Supports GenoMed
FOR IMMEDIATE RELEASE
Contact:
David W. Moskowitz MD
CEO, GenoMed
Tel. 314.983.9938
dwmoskowitz@genomed.com
Mr. Lawrence Guyot
Editor, Guyot's Newsletter
Tel. 202-332-5157
margaretkibbee@ymail.com
ST. LOUIS—December 21, 2009—GenoMed® (OTC Pink Sheets GMED.PK), the Public Health Company™, announced today that longtime civil rights activist Lawrence Guyot has published GenoMed's story in his monthly newsletter.
The article, entitled "A Modern Day Tuskegee—and What's Really Wrong with U.S. Healthcare" (http://www.genomed.com/images/guyot_dec09nl.pdf) was written by GenoMed's CEO, David Moskowitz MD.
Mr. Guyot, one of the leaders of the civil rights movement, was born in Pass Christian, Mississippi. As a 21 year old student at Tugaloo College in 1960, he helped found SNCC, the Student Nonviolent Coordinating Committee. In 1964, Mr. Guyot directed the Freedom Summer Project in Hattiesburg, Mississippi. That same year, he was elected chairman of the Mississippi Freedom Democratic Party. He was unable to accompany the delegation to the Democratic National Convention in Atlantic City, New Jersey because he was jailed for registering black voters. The MDFP's actions in New Jersey ultimately led to the DNC desegregating future conventions and the party itself.
Mr. Guyot has been featured in a number of documentaries, including Eyes on the Prize, Making Sense of the Sixties, The War on Poverty and Tales of the FBI. In addition to his monthly newsletter, he is a frequent TV guest on CNN and Fox News.
Dr. Moskowitz said, "I am enormously proud to have such a distinguished leader of the civil rights movement stand up for me and my company, GenoMed."
Dr. Moskowitz continued, "My paper showing how to prevent at least 90% of kidney failure was published in September, 2002. Although kidney failure claims the lives of 100,000 Americans every year, it affects African-Americans 5 times more, and Hispanics 3 times more, than whites. Medicare currently spends $40 billion a year on this disease."
Dr. Moskowitz ended by saying, "Hopefully, Mr. Guyot's endorsement will spur Medicare to call me so that together we can rid our country of this awful disease."
midastouch017
15 년 전
GenoMed Partners with The Mane Event to Eradicate Dialysis in St. Louis
FOR IMMEDIATE RELEASE
Contact:
David W. Moskowitz MD
CEO, GenoMed
Tel. 314.983.9938
dwmoskowitz@genomed.com
Gerald Shelton
The Mane Event
8327 Olive Blvd.
St. Louis, MO 63132
Tel. 314.363.0570
bc23@sprint.blackberry.net
ST. LOUIS—November 23, 2009—GenoMed® (OTC Pink Sheets GMED.PK), the Public Health Company™, announced today that it has begun partnering with St. Louis barbershops and hair salons to keep their customers from going on kidney dialysis.
GenoMed's first partner is The Mane Event. GenoMed placed a $35 blood pressure cuff in the store over the weekend. Owner Gerald Shelton will encourage his customers to check their blood pressure while they're waiting to be served. People with a blood pressure over 120/80 are urged to contact GenoMed. GenoMed is the only company in the world that has published it can prevent kidney failure due to high blood pressure or diabetes, provided that patients are begun on its treatment early.
Mr. Shelton said, "In my own family and my community, I've seen what a silent killer high blood pressure can be. It's time for us to take charge and help each other out. I'm glad a company like GenoMed is reaching out."
Said David Moskowitz MD FACP, GenoMed's CEO and Chief Medical Officer, "I'm thrilled to be working with Mr. Shelton, who saw from the very beginning how useful a blood pressure machine would be for his customers."
Dr. Moskowitz continued, "GenoMed aims to place blood pressure machines in most of the barber shops, beauty shops, and laundromats in the city and county of St. Louis—wherever people have time on their hands. It's impossible to know your blood pressure unless you check it. And it's impossible for blood pressure to hurt you if you treat it right. People need to get in the habit of checking their blood pressure at least once a month."
Dr. Moskowitz ended by saying, "We're making it easier for people with high blood pressure to find out who they are, and to control their pressure better. GenoMed takes its public health obligation very seriously. Ours is the only paper in the medical literature showing that most kidney failure can be prevented. Even if nobody else in healthcare or public health will take the practical steps to eradicate kidney failure, we will."
About GenoMed (www.genomed.com)
midastouch017
15 년 전
GenoMed to MO Gov. Nixon: "We Can Save Medicaid $32.5 M by June."
FOR IMMEDIATE RELEASE
Contact:
David W. Moskowitz MD
CEO, GenoMed
Tel. 314.983.9938
dwmoskowitz@genomed.com
ST. LOUIS—November 16, 2009—GenoMed® (OTC Pink Sheets GMED.PK), the Public Health Company™ that is pioneering Next Generation Disease Management, announced today that it can save Medicaid $32.5 million by June, 2010.
Like many states during the current Depression, Missouri's revenues have fallen far short of expenditures. As a result, Governor Jay Nixon has recently cut over $600 million from the state budget, including $32.5 million from Medicaid, primarily by reducing payments to nursing homes and home health agencies.
GenoMed has identified a way to effect the same savings, while actually improving patient outcomes.
Missouri Medicaid currently spends 35% of its total budget on acute-care inpatient hospitalizations, or $1.5 billion. The national average is 25%, meaning that Missouri spends a lot more of its Medicaid budget on hospitalizations than most states. If elderly patients could be kept healthier and out of the hospital, Missouri Medicaid costs could be slashed. GenoMed's cutting-edge, genomics-based medicine can accomplish this.
Said David Moskowitz MD FACP, GenoMed's CEO and Chief Medical Officer, "Two diseases in the elderly consume an extraordinary amount of money: heart failure and emphysema. Every time a patient goes to the Emergency Room for shortness of breath, it costs around $10,000. If they're admitted to the hospital from the ER, it can easily cost $50,000. These patients are easy to identify and to help. We've published how to keep patients with heart failure and emphysema out of the hospital by delaying the progression of their disease."
Dr. Moskowitz ended by saying, "We'd like to be able to prove ourselves here in Missouri, the Show Me state. Next year's budget shortfall is projected to be even worse. WIth healthcare costs rising so fast in the US, and state revenues falling, all 50 Medicaid offices should be interested in GenoMed."
About GenoMed (www.genomed.com)
midastouch017
15 년 전
What can GMED shareholders do to raise our company's stock price?
Thanks for asking!
The best way for our stock price to rise is if people knew about us. As luck would have it, the current healthcare reform debate is a perfect opportunity for that to happen.
President Obama has called for prevention, and cost-cutting.
As far as I can tell, we're the only entity in healthcare that can do both. So this may be our time for national attention.
Specifically, here are two op-ed pieces. If you agree with them, send the links to your friends. If any of your friends are healthcare reporters, so much the better!
http://tinyurl.com/healthcrime
http://tinyurl.com/DavidWashingtonMoskowitz
Dave Moskowitz MD
CEO & CMO
GenoMed, Inc
sam1933
15 년 전
Prevention is the best move to counter the worsening problem on kidney disease in the country.
Council for Health and Development /philippines
The burden of renal diseases
About 1.2 million Filipinos today are suffering from kidney diseases, requiring either dialysis or a kidney transplant for them to live. Among the leading causes of kidney failure in the country are diabetes (41%), inflammation of the kidney (24%) and high blood pressure (22%).
According to the Department of Health, kidney disease is now one of the top ten causes of death among Filipinos wherein 7,000 die annually due to kidney malfunction. Because of the increasing number of Filipinos with kidney disease, it is now considered among the top seven health problems in the country.
Worldwide, there is also an alarming level of kidney disease with more than 500 million persons suffering from some form of kidney damage. Over 1.5 million of them are kept alive either through dialysis or transplantation. Every year, over 12 million individuals die prematurely of cardiovascular diseases linked to chronic kidney disease.
Costly treatment
In the Philippines, the treatment of kidney diseases is very costly and unaffordable.
Dialysis treatment uses artificial devices to perform the function of the kidney at about 15%, which is enough to sustain life but needs to be performed adequately on a regular basis (2-3 times a week) for life. Patients without sufficient dialysis are weak and show many of the symptoms that led to their diagnosis. Malnourished and unable to work, they tend to survive only until the next dialysis treatment. A patient has to spend P25,000 to P46,000 a month or P300,000 to P552,000 a year for his or her dialysis. Maintenance medication costs about P20,000 a month.
Kidney transplantation offers the best option for patients with kidney failure as shown by foreign and local studies, according to Romina Angangco Danguilan, chair of the NKTI’s Department of Adult Nephrology. In her study, she noted that the quality of life of a transplant patient is superior to one on dialysis. Kidney transplantation cost ranges from P500,000 to a million. Post-operation medication costs about P12,000 a month.
Because treatment is very expensive and draining to the pocket, it was reported that in 2007, only 73% of Filipino patients with kidney failure were able to afford necessary treatment.
No government support
Patients with PhilHealth coverage can only claim half of the cost of their treatment and cash out for the remaining cost. According to National Kidney Transplant Institute, only 15% of the partially-subsidized patients are PhilHealth members.
Poor kidney patients survive through assistance and borrowings from relatives and friends. Many of them had to beg around for funds from politicians and charitable organizations to pay for their treatment. Even patients who can afford admit that the burden of their treatment cost is heavily draining their families’ resources.
Dr. Lyn Almazan-Gomez, former president of the Philippine Society of Nephrologists said that there is no “free treatment” for kidney diseases. “It would be very draining for the government to shoulder treatment costs for renal patients considering the amount involved,” said Dr. Remedios De Belen-Uriarte, Department Manager of the Renal Disease Control Program of the National Kidney Transplant Institute (NKTI). She said that with limited income and resources, even NKTI can hardly afford to expand its services.
The NKTI is the government’s specialty health facility for kidney transplant and kidney-related diseases. In its out-patient hemodialysis unit, about two-thirds of the patients are pay patients who are able to afford the full amount of treatment costs and are given priority in the dialysis treatments. Only one-third of the patients are relatively poor service patients who avail of the discounts on hospital fees and charges given by the social services section but would have to wait for days to acquire a slot in the dialysis treatment. Regularity of dialysis treatment is very crucial for kidney patients because delay in such treatments would mean danger and may call for more expensive emergency procedures if not attended to immediately.
In 2007, NKTI records showed that of the 336 patients who were given transplantation procedures, 231 or 69% were pay patients and only 105 or 31% were service patients.
Prevention is best move
Prevention is the best move to counter the worsening problem on kidney disease in the country.
Kidney diseases are preventable, according to Dr. Uriarte. She emphasized the importance of early recognition of the causes to prevent or delay the development of kidney problems that usually end to kidney failure. That is why the REDCOP or Renal Disease Control Program under the NKTI, gives emphasis to the prevention aspect of controlling the spread of kidney diseases, according to Dr. Uriarte.
Playing a major role in the prevention of renal diseases, of course, is having a healthy lifestyle, which includes proper nutrition, regular exercise and timely physical check up.
The government appears to be giving less attention to combat the kidney disease problem. The Department of Health has no specific program to address this. Dr. Uriarte pointed out that no single centavo is given by the government in the campaign against renal diseases. She said that REDCOP depends on the funds that NKTI allocates to the program from the institution’s income.
Dr. Eleanor A. Jara, Executive Director of Council for Health and Development (CHD) said that it is the responsibility of the government to decisively exert the effort to address the worsening problem on renal diseases in the country given the prevailing economic difficulties confronting poor Filipinos these days.
Much more with the prevailing economic difficulties, the government must prioritize people’s health. This means increasing the share of health in the national budget from the less than one percent at present to as much as five percent of the country’s total production following the World Health Organization’s prescription. It also means unburdening the people in paying onerous debts incurred by the government and decreasing the budget for huge military spending.
Sources: info@worldkidneyday.org; www.sunstar.com.ph/static/dav/; sree1010.wordpress.com/2009/02/04;
abs-cbnnews.com/07/29/2008;
www.positivenewsmedia.net/.../Gov;
PIA Press Release, 12-04-2008; REDCOP/NKTI
sam1933
15 년 전
GenoMed's earlier memorandum: the story in full>>>>>>>>>>>
Health
GenoMed, LaSalTech sign pact for preventive medicine venture
BACOLOD CITY, May 26 (PNA) - Bacolod internet services firm LaSalTech has been tapped by GenoMed, a US-based disease management company, as anchor partner in a venture that will introduce preventive molecular medicine to the Philippines and later to other parts of the world.
The GenoMed-Filipino venture will include GenoMed, Inc., a public US company, and LaSalTech Inc., a private Philippine company, their joint statement said.
Dr. David Moskowitz, GenoMed chief executive officer, arrived in Bacolod recently to sign a memorandum of understanding with LaSalTech represented by its chairman Bro. Rolando Dizon.
"The venture will include GenoMed's protocols to keep diabetic and hypertensive patients off the kidney machine, a telecommunication company to help us market and deliver our medical advice by cell phone, call centers to answer patients' questions in real time, and a generic drug company to offer the drugs we use at a low enough price for even the poorest Filipino to afford,” Moskowitz said in a statement.
He identified Globe Telecom Inc. as the telecommunications company that will help deliver GenoMed protocols by cellphone, and a catastrophic hospitalization insurance company as another potential partner.
Late last week, they began talks with additional potential partners, including a generic drug company and a chain of retail pharmacies.
“In the future, we'd like to add a network of discount physicians, clinical laboratories, dentists and optometrists. Retail pharmacists could check patients' blood pressures if doctors were too busy," Moskowitz said.
Dizon said LaSalTech is assisting GenoMed in the organization and management of the venture, including tapping of potential partners.
“LaSalTech will support David’s group to get things started,” he said, adding that the GenoMed-LaSalTech partnership is historic, and would be part of initiatives to make Negros Occidental go beyond its monocrop economy.
“We have to take very aggressive efforts in developing industries not dependent on sugar,” Dizon said.
For its part, GenoMed has acknowledged in its statement that foreign companies like theirs are limited by the Philippine law to a maximum of 40-percent ownership of any joint venture.
"If we succeed at a state-of-the-art, prevention-based healthcare solution for even the poorest Filipino, we will be able to export it to other countries, especially the US President Barack Obama has called for just such a solution.
"Unfortunately, I haven't found a single American partner despite a decade of searching,” Moskowitz said.
But in the Philippines, he said, he has found many potential Philippine partners after only a month.
Last month, GenoMed has announced that it has been in discussions to purchase Offshore HRM, a medical coding company which recently established a 200-person call center in Bacolod.
Moskowitz said GenoMed is engaged in two major activities, managing patients and doing research, and Offshore HRM will allow their company to manage patients on a large scale, and help them market to patients in the Philippines where there is an extremely high prevalence rate of diabetes.
Offshore HRM, which recently trained the Philippines’ first five medical coding professionals, will also recruit Filipino physicians and nurses and train them in GenoMed's algorithms to take care of paying patients. (PNA)
http://positivenewsmedia.net/am2/publish/Health_21/GenoMed_LaSalTech_sign_pact_for_preventive_medicine_venture.shtml
TMI proudly supports Genomed, Inc. and his CEO's remarkable initiative providing free on-line medical consultation.
http://www.technicalmedical.com/en/tmi_news.html
midastouch017
15 년 전
GenoMed in Discussions with Philippines Dept of Health to Eradicate Kidney Failure
FOR IMMEDIATE RELEASE
Contact:
David W. Moskowitz MD
CEO, GenoMed
Tel. 314.983.9938
dwmoskowitz@genomed.com
ST. LOUIS—August 25, 2009—GenoMed® (OTC Pink Sheets GMED.PK), the Public Health Company™, announced today that it has entered into discussions with the Department of Health of the Philippines to eliminate 95% of kidney failure from that country.
This follows on GenoMed's earlier memorandum of understanding with LaSalTech, a call center in Bacolod, Republic of the Philippines (RP). GenoMed will teach LaSalTech physicians its "recipe" and they, in turn, will recommend it to the 20 million adults with high blood pressure in the RP. An electronic record will be created for each patient, and GenoMed will supervise the operation from its St. Louis headquarters.
GenoMed and LaSalTech are also in discussions with a chain of retail pharmacies which would serve as the point of contact with the country's 20 million hypertensive patients.
Said Dr. Moskowitz, GenoMed's CEO, "We're delighted that the Department of Health of the Philippines is interested in supporting us. Their involvement is crucial."
Dr. Moskowitz continued, "If we succeed at a state-of-the-art, prevention-based healthcare solution for even the poorest Filipino, we will be able to export it to other countries, especially the US. President Obama has called for just such a solution. Unfortunately, Medicare has had no interest whatsoever in cutting 10% of its budget, or $35 billion a year."
Dr. Moskowitz ended by saying, "The Philippine government, on the other hand, simply can't afford to dialyze 20,000 new patients each year, and is committed to prevention. Our partner, LaSalTech, and Brother Rolando Dizon, its Chairman, helped make this happen. This is a great day for GenoMed's shareholders. We finally get a chance to show our stuff in a nation of 90 million."
About LaSalTech (www.lasaltech.com)
LaSalTech was the first Internet service provider in Bacolod, a city of 750,000 in Negros Occidental, the sugar-growing province of the Philippine Islands. Several years ago, LaSalTech entered the growing business of Call Centers. Brother Rolando Dizon, its Chairman, has been a trusted advisor to Philippine Presidents. He helped Cory Aquino overthrow former President Ferdinand Marcos.
About GenoMed (www.genomed.com)
GenoMed is a Next Generation Disease Management company that aims to deliver the best patient outcomes at the lowest possible cost. GenoMed wants to prove that it can arrest diabetes, hypertension, and emphysema even in a developing country with scant resources like the Philippines. GenoMed intends to be the global healthcare provider of choice, especially for America's 50 million uninsured.
sam1933
15 년 전
In the Media
Wednesday, 29 July 2009 08:47
Avoiding Dialysis with Dr. Moskowitz
Listen to an interview with Dr. Moskowitz on Natural Health Radio. Dr. Moskowitz discusses GenoMed's approach to preventing dialysis and kidney failure. To hear the entire interview, go to the Natural Health Radio website.
http://akcsm.com/radio/NHR-2009-07-29-Avoiding%20Dialysis-Kidney-Heart-Disease-with-Dave-Moskowitz.html
Date / Length: 7/23/2009 12:00 PM - 1 hr
A 'New Age' Tuskegee Medical Crime?
Harvard and MIT trained practicing nephrologist, and CEO/founder of OTC listed GenoMed, Inc., (http://genomed.com), David Moskowitz, MD, often finds himself at odds with mainstream medicine, including powerful St Louis hospital systems defending the 'sick care' recurring revenue streams associated with chronic renal dialysis treatment. Dr. Moskowitz claims he has the medical innovation, and documented research outcomes to prove his claim that kidney disease can be prevented, and even reversed - thus eliminating the patient's dependency on dialysis. Listen to Dr. Moskowitz.
http://www.blogtalkradio.com/2healthguru/2009/07/23/A-New-Age-Tuskegee-Medical-Crime
sam1933
15 년 전
A 'New Age' Tuskegee Medical Crime?
Date / Length: 7/23/2009 12:00 PM - 1 hr
Harvard and MIT trained practicing nephrologist, and CEO/founder of OTC listed GenoMed, Inc., (http://genomed.com), David Moskowitz, MD, often finds himself at odds with mainstream medicine, including powerful St Louis hospital systems defending the 'sick care' recurring revenue streams associated with chronic renal dialysis treatment. Dr. Moskowitz claims he has the medical innovation, and documented research outcomes to prove his claim that kidney disease can be prevented, and even reversed - thus eliminating the patient's dependency on dialysis. Is Moskowitz a clinical 'disruptor' and medical innovator who threatens the mainstream, or an eccentric, perhaps unrealistic, practitioner having drunk the 'kool-aide' at perpetual odds with prevailing convention and medical standards? You be the judge.
http://www.blogtalkradio.com/2healthguru/2009/07/23/A-New-Age-Tuskegee-Medical-Crime
sam1933
15 년 전
GenoMed’s Observation of Major Racial Difference in Prostate Cancer Confirmed
July 16th, 2009 by towardfivequot
GenoMed Inc announced today that it has received independent confirmation of an observation the Company orignally made in 2002 that prostate cancer behaves differently in ashen and black men. In black men, angiotensin II promotes prostate cancer, and ACE inhibitors are heedful. But in unblemished men, angiotensin II protects against prostate cancer, and ACE inhibitors promote prostate cancer.
In 2002, GenoMed published a surprising be produced end: that vim of angiotensin I-converting enzyme was positively associated with prostate cancer and PSA levels in African American men, but inversely associated with prostate cancer and PSA levels in Caucasians (Moskowitz DW. Is angiotensin I-converting enzyme a “master” affliction gene? Diabetes Technol Ther. 2002;4(5):683-711. Submit 9, p. 697; PDF put available at: http://www.genomed.com/pdf/is.angiotensin.pdf). This was the first suggestion that ACE inhibitors, which block the building of angiotensin II, might protect atrocious men against prostate cancer, but espouse prostate cancer in white men.
This observation was confirmed in a subsequent paper published by GenoMed last summer (Moskowitz DW, Johnson FE. The central task of angiotensin I-converting enzyme in vertebrate pathophysiology. Curr Unequalled Med Chem. 2004;4(13):1433-54), in which ACE inhibitors were found to increase the odds of prostate cancer in a predominantly white masculine veteran hospital population by a factor of 4.7 (Table 3). A “wiring diagram” fitting for prostate cancer in white men was proposed (Figure 12, p. 1446; PDF put within reach at: genomed.com/pdf/ACE_vertebrate_pathophysiology.pdf).
GenoMed’s surprising result was confirmed by Professor Marek Pawlikowski and his put together at the University of Lodz in Poland in move up published in late 2004, which GenoMed recently became aware of(medscimonit.com/pub/vol_10/no_11/4168.pdf).
Said Dr. David Moskowitz, GenoMed’s CEO and Chief Medical Policewoman, “Dr. Pawlikowski’s bracket acclimatized a prostate cancer cell line, DU-145, that was derived from a Caucasian male. They found in vitro exactly what we found in vivo using genomic epidemiologic and pharmacoepidemiologic facts in human compliant populations: angiotensin II surprisingly inhibited the growth of the Caucasian man’s prostate cancer cells. The legend probe whim be to look at if they observe the opposite result with the CRL-2422 prostate cancer chamber belt, which is derived from an African American patient. Our data predict that ACE inhibitors see fit slow the progress of the CRL-2422 prostate cancer cells, and angiotensin II command promote it, which is what angiotensin II does to most cancer lines.”
Added Dr. Moskowitz, “The public health message is actually undisputed: every white man on an ACE inhibitor should be more closely monitored for prostate cancer with a PSA be open every 6-9 months. On the other transfer manacles, every black gink with prostate cancer should consider taking an ACE inhibitor to slow down growth of the tumor.”
About GenoMed
GenoMed, Inc. is a Next Generation DM(TM) company whose mission is to improve patient outcomes by identifying the molecular pathways that cause murrain. A St. Louis Business Journal article (http://www.stlouis.bizjournals.com/stlouis/stories/2002/05/13/story8.html) first reported that the company applied for patents based on its finding that the ACE gene is associated with many garden-variety diseases. The assemblage is currently marketing its protocols on the side of preventing kidney incompetent due to diabetes and consequential blood pressure, and delaying the progression of emphysema. The company is also conducting free clinical trials repayment for all cancers except prostate cancer in white men, as well as all viral diseases except herpes viruses. To enroll in GenoMed’s at large clinical burr under the saddle for West Nile virus, artlessly click on the West Nile virus together at http://www.genomed.com
Repository Harbor Affirmation
This press release contains forward looking statements, including those statements pertaining to GenoMed, Inc.’s (the Company’s) treatments. The words or phrases “ought to,” “should,” “may,” or be like expressions are intended to identify “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could fall out materially from those projected in the dispatch looking statements as a denouement develop of a tally of risks and uncertainties. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. Unless in another manner required by applicable law, we specifically disclaim any demand to update any forward-looking statements to demonstrate occurrences, developments, unanticipated events or circumstances after the antiquated of such statement.
Contact:
David Moskowitz MD FACP
GenoMed, Inc.
dwmoskowitz@genomed.com
tel. 314-983-9933
genomed.com
midastouch017
15 년 전
eps. Jeanette Mott Oxford and Rev. James Morris Endorse GenoMed's "Dialysis-Free in Five" Campaign
FOR IMMEDIATE RELEASE
Contact:
David W. Moskowitz MD
CEO, GenoMed
dwmoskowitz@genomed.com
Tel. 314.983.9938
Lionel Nixon
Director, Field Operations
Legislative District 58
Missouri House of Representatives
lionelnixon@yahoo.com
Tel. 314-532-9902
The Honorable Jeanette Oxford
Representative, District 59
Missouri House of Representatives
jmo4rep@juno.com
Tel. 314-775-8940
ST. LOUIS—July 20, 2009—GenoMed® (OTC Pink Sheets GMED.PK), the Public Health Company™, announced today with pride that the Honorable Jeanette Mott Oxford and the Honorable James Morris have endorsed its campaign to make their districts at least 90% free of kidney disease by 2014.
GenoMed published in 2002 how to reverse early-stage kidney failure in patients with type 2 diabetes or high blood pressure. These two diseases cause over 90% of kidney failure that requires dialysis with the kidney machine.
Both Rep. Oxford's district in south St. Louis and Rep. Morris's district in north St. Louis each contain about 35,000 people. Their districts are among the oldest, most population-dense, and most ethnically and economically diverse districts in the state, including significant numbers of families living in poverty.
David W. Moskowitz, MD FACP, GenoMed's CEO and Chief Medical Officer, said "Education is the key to eliminating 90% of new cases of kidney failure. We'll be working with primary care providers and pharmacists in Districts 58 and 59 to identify and treat patients with diabetes and high blood pressure. We'll adjust their medications intensively over a period of 2 to 3 months. By the end of 2010, we hope to have covered every patient in both Districts."
Dr. Moskowitz added, "The drugs we use are generic and cheap. GenoMed's fees are low enough for everybody in these Districts to afford. Preventive molecular medicine is actually quite inexpensive, about 100 times cheaper than dialysis."
Dr. Moskowitz ended by saying, "I'm thrilled that Rep. Oxford and Rep. Morris are courageously leading their Districts to better public health. They live Missouri's motto, Salus populi suprema lex esto ["Let the health of the people be the supreme law"]. Their Districts are lucky to have them."
About GenoMed
GenoMed is a Next Generation Disease Management company that aims to deliver the best patient outcomes at the lowest possible cost. As the only Public Health Company™, GenoMed aims to arrest diabetes, hypertension, and emphysema everywhere. Please contact Dr. Moskowitz if you have one of these diseases.
Hot Features
프리미엄
무료로 등록하여 실시간 주식 시세, 대화형 차트, 실시간 옵션 플로우 등을 받아보세요.
TFMG
5 년 전
ValueInvestor15
8 년 전
T695
8 년 전
pj McMulligan
12 년 전
dshade
15 년 전
